Investigated for use/treatment in duodenal ulcers, gastric ulcers, gastroesophageal reflux disease (GERD), and gastrointestinal diseases and disorders (miscellaneous).
Mode of Action:
Lansoprazole has an asymmetric sulfur in its chemical structure and is commercially marketed as a racemic mixture. Both the (R)- and (S)-enantiomers of lansoprazole inhibit acid formation in isolated canine parietal cells and (H'+'/K'+')-ATPase in canine gastric microsomes with nearly the same potency.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs